跳至主要内容
临床试验/NCT04112381
NCT04112381进行中(未招募)不适用

A Pivotal Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor

InSightec14 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2020年6月30日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
InSightec
入组人数
51
试验地点
14
主要终点
Device and procedure related adverse events

研究概览

简要总结

The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women age 22 years or older
  • Diagnosis of medication-refractory Essential Tremor
  • Has previously underwent an Exablate index procedure in a clinical trial or in a commercial setting at least 9 months prior to enrolling in this trial
  • Able to communicate sensations during the Exablate thalamotomy procedure

排除标准

  • Has experienced any non-transient neurological event or worsening following the Exablate index procedure
  • Presence of unknown or MR unsafe devices anywhere in the body
  • Non-transient hemiparesis as determined by physical examination
  • Clinically significant abnormal speech function as determined by a speech pathologist
  • Pregnant or breastfeeding
  • Unstable cardiac status
  • Behavior(s) consistent with ethanol or substance abuse
  • History of bleeding disorder
  • Has received anticoagulants within one month of Exablate procedure
  • Cerebrovascular disease
  • Intracranial tumor
  • Active or suspected acute or chronic uncontrolled infection
  • Has previously had deep brain stimulation or a prior stereotactic ablation of the basal ganglia or thalamus
  • Implanted objects in the skull or the brain
  • Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research
  • Unable to communicate with the investigator and staff

结局指标

主要结局

Device and procedure related adverse events

时间窗: 3 months

rate of adverse events following the Exablate secondary procedure

次要结局

未报告次要终点

研究者

发起方
InSightec
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验

Bilateral Treatment of Medication Refractory... | 临床试验